WEST-WARD

SAFETY DATA SHEET

1. Identification

Product identifier Oxycodone and Acetaminophen Tablets USP, 5mg/325mg CII

Other means of identification

Product code 5mg/325mg round, white tablet, debossed with product identification "54 543" on one side, and

score on the other.

Recommended use For relief of moderate to moderately severe pain

Recommended restrictions None known.

Manufacturer/Importer/Supplier/Distributor information

Company name West-Ward Pharmaceuticals Corporation

Address 1809 Wilson Road

Columbus, Ohio 43228

Telephone (614) 276-4000 Emergency phone number (614) 276-4000

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Not classified.

OSHA defined hazards Not classified.

Label elements

Hazard symbol None.

Signal word Warning

Hazard statement This is a pharmaceutical product designed to be prescribed by a licensed health care

professional. Should any person while using this product observe any adverse health effects, they

should seek medical treatment.

Precautionary statement

Prevention Observe good industrial hygiene practices.

Response Wash hands after handling.

Storage Store away from incompatible materials. Protect from moisture. Store at 20 – 25 °C (68 - 77°F).

Disposal Incineration of waste at an approved USEPA incinerator is recommended.

Hazard(s) not otherwise

classified (HNOC)

None known.

3. Composition/information on ingredients

Substances

Chemical name	Common name and	CAS number	%
	synonyms		
Acetaminophen		103-90-2	325mg
Oxycodone Hydrochloride		124-90-3	5mg

Composition comments Refer to Physician's Desk Reference for common components present at <1%

4. First-aid measures

Inhalation If dust from the material is inhaled, remove the affected person immediately to fresh air. Call a

physician if symptoms develop or persist.

Skin contact Wash off with soap and water. Get medical attention if irritation develops and persists.

Eye contact Rinse with water. Get medical attention if irritation develops and persists.

Ingestion Rinse mouth. Get medical attention if symptoms occur. If ingestion of a large amount does occur,

call a poison control center immediately.

Oxycodone and Acetaminophen Tablets USP, 5mg/325mg CII 926512 Version #: 01 Revision date: - Issue date: 08-May-2015 Most important symptoms/effects, acute and delayed

The most common symptoms include: drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, and sweating

Indication of immediate medical attention and special treatment needed

In the case of overdose, the primary management should be the reestablishment of adequate ventilation with mechanical assistance of respiration, if required. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation. Treat symptomatically.

General information

Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

5. Fire-fighting measures

Suitable extinguishing media Unsuitable extinguishing media Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2). Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting equipment/instructions

Use water spray to cool unopened containers.

Specific methods

Use standard firefighting procedures and consider the hazards of other involved materials.

General fire hazards No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Keep unnecessary personnel away. Wear appropriate personal protective equipment (See Section

Methods and materials for containment and cleaning up

Sweep up and place into a proper container for disposal. Minimize dust generation and accumulation. Collect dust using a vacuum cleaner equipped with HEPA filter. Following product recovery, flush area with water. Incineration of waste at an approved USEPA incinerator is recommended. Controlled substances must be destroyed following DEA guidelines for witnessed destruction of the product beyond reclamation.

Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Avoid contact with eyes, skin, and clothing. Avoid breathing dust. Wash hands thoroughly after handling.

Conditions for safe storage, including any incompatibilities

Store at $20-25\,^{\circ}\text{C}$ (68 - 77°F). Protect from moisture. Keep locked up and out of the reach of children. Dispense in a tight, light-resistant container as defined in the USP/NF. Store away from

Value

incompatible materials (see Section 10 of the SDS).

Type

8. Exposure controls/personal protection

Occupational exposure limits

Components

US. OSHA Table Z-1 Limits for Air Contaminants (29 CFR 1910.1000)

	7 1.	14.40	
Dust	PEL	5 mg/m3	Respirable fraction.
		15 mg/m3	Total dust.
US. OSHA Table Z-3 (29 CFR 1	910.1000)		
Components	Туре	Value	Form
Dust	TWA	5 mg/m3	Respirable fraction.
		15 mg/m3	Total dust.
		50 mppcf	Total dust.
		15 mppcf	Respirable fraction.
US. ACGIH Threshold Limit Va	lues		
Components	Туре	Value	Form
Dust	TWA	3 mg/m3	Respirable particles.
		10 mg/m3	Inhalable particles.

Form

Biological limit values

No biological exposure limits noted for the ingredient(s).

Appropriate engineering

controls

Ventilation should be matched to conditions.

Individual protection measures, such as personal protective equipment

Eye/face protection

None required for consumer use. In laboratory, medical or industrial settings, safety glasses with side shields are recommended. The use of goggles or full face protection may be required depending on the industrial exposure setting. Contact a health and safety professional for specific information.

Skin protection

Hand protection

For consumer use, no unusual precautions are necessary.

Other

None required for consumer use. In laboratory, medical or industrial settings, gloves and lab coats are recommended. The use of additional personal protective equipment such as shoe coverings, gauntlets, hood or head coverings may be necessary. Contact a health and safety professional for

specific information.

Respiratory protection

None required for consumer use. Respirators may be required for certain laboratory and manufacturing tasks if engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (where exposure limits have not been established). Workplace risk assessments should be completed before specifying and implementing respirator usage. All respirators must conform to specifications for efficiency and performance. In the United States of America, if respirators are used, a program should be instituted to assure compliance with OSHA Standard 29 CFR 1910.134. Respirator type: Air-purifying respirator with an appropriate, air-purifying filter, cartridge or canister. Contact a health and safety professional or manufacturer for specific information.

Thermal hazards

Wear appropriate thermal protective clothing, when necessary.

General hygiene considerations

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

9. Physical and chemical properties

Appearance

Solid. **Physical state** Form Tablet. Color White. Odor None.

Odor threshold Not available. Not available. Ηq Melting point/freezing point Not available. Initial boiling point and boiling Not available.

range

Not available. Flash point **Evaporation rate** Not available. Not available. Flammability (solid, gas) Upper/lower flammability or explosive limits

Flammability limit - lower

(%)

Not available.

Flammability limit - upper

(%)

Not available.

Not available. Explosive limit - lower (%) Not available. Explosive limit - upper (%)

Vapor pressure Not available. Not available. Vapor density Not available. Relative density

Solubility(ies)

Slightly soluble Solubility (water) Partition coefficient Not available.

(n-octanol/water)

Not available. **Auto-ignition temperature Decomposition temperature** Not available. **Viscosity** Not available.

10. Stability and reactivity

Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

Material is stable under normal conditions. Chemical stability

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials. Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

No hazardous decomposition products are known.

11. Toxicological information

Information on likely routes of exposure

Not expected to be hazardous in final pharmaceutical form. Mechanical processing may generate Inhalation

dust. Inhalation of dusts may cause respiratory irritation.

Skin contact Not expected to be hazardous in final pharmaceutical form. Mechanical processing may generate

dust. Dust or powder may irritate the skin.

Not expected to be hazardous in final pharmaceutical form. Mechanical processing may generate Eye contact

dust. Dust may irritate the eyes.

Ingestion Ingestion may cause irritation and malaise.

Symptoms related to the physical, chemical and toxicological characteristics The most common symptoms include: drowsiness, lightheadedness, dizziness, sedation,

shortness of breath, nausea, vomiting, and sweating

Information on toxicological effects

May be harmful if swallowed in large quantities. Acute toxicity

Species Test Results Components

Acetaminophen (CAS 103-90-2)

Acute Oral

LD50

Rat 1944 mg/kg

Skin corrosion/irritation Prolonged skin contact may cause temporary irritation.

Serious eye damage/eye

irritation

Dust may irritate the eyes.

Respiratory or skin sensitization

Respiratory sensitization Not a respiratory sensitizer.

Skin sensitization This product is not expected to cause skin sensitization.

Germ cell mutagenicity This product is not expected to be mutagenic.

Animal studies to evaluate the carcinogenic potential have not been performed. Carcinogenicity

IARC Monographs. Overall Evaluation of Carcinogenicity

Acetaminophen (CAS 103-90-2) 3 Not classifiable as to carcinogenicity to humans.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

Reproductive toxicity Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women.

This product passes into breast milk. Breast-feeding is not advised in mothers being treated.

Specific target organ toxicity -

single exposure

Not classified.

Specific target organ toxicity -

repeated exposure

Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver

transplant and death. Most of the cases of liver injury are associated with the use of

acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one

acetaminophen-containing product.

Aspiration hazard Due to the physical form of the product it is not an aspiration hazard. Further information See package insert.

12. Ecological information

Ecotoxicity The product is not classified as environmentally hazardous.

Components Species Test Results

Acetaminophen (CAS 103-90-2)

Aquatic

Crustacea EC50 Water flea (Daphnia magna) 6.1 - 14 mg/l, 48 hours
Fish LC50 Fathead minnow (Pimephales promelas) 814 mg/l, 96 hours

Persistence and degradability

No data is available on the degradability of this product.

Bioaccumulative potential

No data available.

Mobility in soil

Product components are soluble in water and will slowly dissolve and disperse.

Other adverse effects

None.

13. Disposal considerations

Disposal instructions

Collect and reclaim or dispose in sealed containers at licensed waste disposal site.

Local disposal regulations

Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging

Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to

Not applicable.

Annex II of MARPOL 73/78 and

the IBC Code

15. Regulatory information

US federal regulations

This material is not listed on the US TSCA Inventory. Therefore, it can only be used for TSCA exempt purposes such as R&D or drug use.

DEA: Oxycodone and Acetaminophen Tablets USP, 5mg/325 mg are a DEA scheduled II controlled substance.

FDA: Oxycodone and Acetaminophen Tablets USP, 5mg/325mg, CII are an approved prescription medication.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - No

Delayed Hazard - No Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

Oxycodone and Acetaminophen Tablets USP, 5mg/325mg CII

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous Nο

chemical

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

Not regulated.

(SDWA)

Drug Enforcement Administration (DEA): This product is a Schedule II Controlled Substance (21 CFR 1308.14)

US state regulations

US. Massachusetts RTK - Substance List

Not regulated.

US. New Jersey Worker and Community Right-to-Know Act

US. Pennsylvania Worker and Community Right-to-Know Law

Not listed

US. Rhode Island RTK

Not regulated.

US. California Proposition 65

This product does not contain a chemical known to the State of California to cause cancer, birth defects or other reproductive harm.

International Inventories

Country(s) or region On inventory (yes/no)* Inventory name

Canada Domestic Substances List (DSL) Nο United States & Puerto Rico Toxic Substances Control Act (TSCA) Inventory No

*A "Yes" indicates this product complies with the inventory requirements administered by the governing country(s).

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

08-May-2015 Issue date

Revision date Version #

1) Oxycodone and Acetaminophen Tablets USP, 5mg/325mg, CII, Package Insert, References

West-Ward Pharmaceuticals Corporation, Columbus, Ohio.

2) PDR - Physicians Desk Reference.

3) Ariel Webinsight. Regulatory and ChemExpert Database.

Disclaimer West-Ward Pharmaceuticals Corporation cannot anticipate all conditions under which this information and

> its product, or the products of other manufacturers in combination with its product, may be used. It is the user's responsibility to ensure safe conditions for handling, storage and disposal of the product, and to assume liability for loss, injury, damage or expense due to improper use. The information in the sheet was written based on the best knowledge and experience currently

available.

Oxycodone and Acetaminophen Tablets USP, 5mg/325mg CII